Skip to content
healthcare.dev

Rituxan Hycela

NDC 50242-108, rituximab and hyaluronidase, injection, solution, from Genentech, Inc..

Product NDC
50242-108
Status
Listed
Labeler
Genentech, Inc.
Dosage form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
BLA
Application
BLA761064
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/50242-108 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • RITUXIMAB120 mg/mL
  • HYALURONIDASE (HUMAN RECOMBINANT)2000 U/mL

Pharmacologic classes

CD20-directed Antibody Interactions [MoA]; CD20-directed Cytolytic Antibody [EPC]; Endoglycosidase [EPC]; Glycoside Hydrolases [CS]

Package NDCNDC-11Package
50242-108-01502420108011 VIAL, SINGLE-DOSE in 1 CARTON (50242-108-01) / 11.7 mL in 1 VIAL, SINGLE-DOSE
50242-108-86502420108861 VIAL, SINGLE-DOSE in 1 CARTON (50242-108-86) / 11.7 mL in 1 VIAL, SINGLE-DOSE

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/3e5b7e82-f018-4eaf-ae78-d6145a906b20
  • Medicare Part B payment limits (ASP)

    GET /v1/drugs/asp?ndc=50242-108

Use it

Look up 50242-108 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/50242-108 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 50242-108. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.